Navigation Links
Amicus Therapeutics Announces First Quarter 2008 Financial Results
Date:5/13/2008

tors presented positive results from Phase 2 clinical trials of Amigal at the American College of Medical Genetics (ACMG) meeting. The data showed that Amigal was generally safe and well-tolerated at all doses evaluated and no drug-related serious adverse events were reported. In addition, Amigal increased the level of the enzyme deficient in Fabry patients in 24 of 26 study subjects, and in a majority of study subjects the treatment resulted in a reduction of kidney GL-3 as measured in urine.

Amicus, along with its partner Shire, has initiated discussions with the U. S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) regarding its plans for Phase 3 clinical evaluation of Amigal. Amicus expects to complete these interactions and provide an update in the second half of 2008, and subject to the outcome of the discussions, the Company plans to initiate the Phase 3 clinical trial in the first half of 2009.

In parallel with the regulatory process, 23 of the original 26 patients continue to be treated with Amigal in the voluntary Phase 2 extension study to monitor long term safety and efficacy. In addition, the Company will evaluate modified doses and dose regimens in these 23 patients. Data from this extension study are expected to be available by Q1 2009, prior to finalization of the Phase 3 protocol.

Gaucher Disease:

Plicera(TM) (isofagomine tartrate) is an investigational, oral therapeutic being developed for the treatment of Gaucher disease. At the ACMG meeting in March, clinical investigators presented full data from a 4 week Phase 2 study in Gaucher patients who switched from enzyme replacement therapy (ERT) with imiglucerase to the pharmacological chaperone Plicera. Results showed that Plicera was generally safe and well tolerated at all doses and increased target enzyme activity levels in a majority of patients. In the trial, GCase activity, as measured in white blood cells, was increased in 20 of the 26 pat
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... 2015 With recent advancements in residential ... government, major companies are getting into the Solar Energy ... mandates for renewable energy production, many homeowners are looking ... Power is a new solar distribution company in California ... allow qualifying homeowners to enjoy the benefits of solar ...
(Date:3/30/2015)... 2015  Multiple new research abstracts suggest walnuts may ... factors. From their impact on colon cancer and certain ... both gut health and vascular health, the research findings ... understanding of walnuts, inner workings. Running March 28 through ... annual meeting attracts an international audience of over 14,000 ...
(Date:3/30/2015)... 30, 2015  NuGene International, Inc. ("NuGene") (OTCQB: ... BioPharma, Inc. has added another internationally recognized researcher ... is an internationally recognized researcher in bio-inspired materials ... at Peking University, China , ... University of North Carolina, Chapel Hill. Following a ...
(Date:3/30/2015)... 2015 US-Australian drug discovery company, Novogen Ltd, ... Inc., and Yale University, on March 27 released pre-clinical ... presented as an oral presentation by Professor Gil ... the 62 nd Annual Scientific Meeting of the ... CA. In both in vitro ...
Breaking Biology Technology:Solara Power Announces Residential Solar Power with No Up-Front Fees 2New Findings Support the Benefits of Eating Walnuts on Overall Health 2New Findings Support the Benefits of Eating Walnuts on Overall Health 3New Findings Support the Benefits of Eating Walnuts on Overall Health 4UCI Professor Zhibin Guan Joins NuGene Advisory Board 2UCI Professor Zhibin Guan Joins NuGene Advisory Board 3Yale University and Novogen Release Data on Cantrixil Mode of Action 2Yale University and Novogen Release Data on Cantrixil Mode of Action 3Yale University and Novogen Release Data on Cantrixil Mode of Action 4
... Incorporated,(Nasdaq: SPEX ) reported a net loss for the three months ended March 31,2008 ... on the company,s on-going Phase 3 clinical trial,in the use of Naturlose for the treatment ... million and reflected the,start-up costs for the trial., , ... ...
... Vista Partners announced today that,it has initiated coverage on ... of Research of Vista Partners stated, "Synvista is one ... across. The,company is conducting four Phase 2 trials in ... a $100M market, could begin to,produce revenues as early ...
... Phase 1c Study Demonstrates Dose-dependent Activity of Antidote ... Biosciences today announced,the Journal of Thrombosis and Haemostasis, ... and Haemostasis, has published the,Phase 1c clinical results ... two-component system comprised of an aptamer-based anticoagulant,RB006, and ...
Cached Biology Technology:Spherix Reports 1st Quarter Earnings 2Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI) 2Regado Biosciences' REG1 Anticoagulation System Study Results Published in the Journal of Thrombosis and Haemostasis 2Regado Biosciences' REG1 Anticoagulation System Study Results Published in the Journal of Thrombosis and Haemostasis 3Regado Biosciences' REG1 Anticoagulation System Study Results Published in the Journal of Thrombosis and Haemostasis 4
(Date:3/23/2015)... Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, announces its biometric payment technology, ... on CNBC television starting March 30 th . ... in New York markets. ... are excited about our new ad campaign following the recent ...
(Date:3/19/2015)... March 19, 2015  NXT-ID, Inc. (NASDAQ: NXTD ... on the growing mobile commerce market, announces its biometric payment ... clip that aired this week on Washington DC,s ... In a segment "The Next Great Thing", host ... way to pay, and ,a really big breakthrough in mobile ...
(Date:3/16/2015)... , March 16, 2015 ... Systems GmbH will present groundbreaking innovations in biometric ... Hanover, Germany .      (Photo: ... latest biometric innovation is well at the forefront: ... generation e-gate made in Germany ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3
... externally-shelled cephalopods that thrived in the tropical oceans ... years their modern soft bodied relatives dumped the ... makes Nautilus ideally suited to discover the evolutionary ... complex coleoid [soft bodied cephalopod] brains say Robyn ...
... prestigious Science Journalism Fellowships from the MBL (Marine Biological ... educational center located in the village of Woods Hole, ... its 23rd year, the MBL,s Science Journalism Program allows ... into the shoes of the scientists they cover" by ...
... Airplanes, submarines and even automobiles of tomorrow may ... for navigation and other purposes. The proprietary system of ... of Panos Datskos, Slo Rajic and Nickolay Lavrik of ... gyroscopes, which are big and costly. Instead, this system ...
Cached Biology News:MBL awards journalism fellowships 2MBL awards journalism fellowships 3Story tips from the Department of Energy's Oak Ridge National Laboratory, June 2008 2Story tips from the Department of Energy's Oak Ridge National Laboratory, June 2008 3
... system features the Vaccinia capping ... components needed to produce a ... of di- or triphosphate RNA ... efficiency capping (virtually 100%) at ...
SDS-OutT Precipitation Reagent...
Extracti-Gel D Detergent Removing Gel...
... imaging system allows scanning of ... large as 40 x 46cm ... 25 microns. This system is ... in the proteomics field and ...
Biology Products: